The IPOX® Week - September 18, 2023

IPOX
Written byIPOX
Published on18 September 2023

Headlines:


  • IPOX® Indexes trade mixed as new U.S. inflation data cautions investors.


  • Arm’s success opens up opportunities for IPOs of Instacart and Klaviyo.


  • ADES sets up largest Saudi IPO YTD. Birkenstock files for $8b NYSE listing.


  • IPOX® SPAC (SPAC) drops 2.91%. No SPACs launch in the U.S. last week.


WEEKLY IPOX® PERFORMANCE REVIEW: Amid option expiration and benchmark index rebalancing, the IPOX® Indexes traded mixed last week. In the U.S., markets reacted to hotter-than-expected U.S. inflation, which rose to 3.7% in August due to a sharp increase in energy prices. Nevertheless, U.S. inflation expectations fell to their lowest in over two years, indicating consumer optimism. As signs of economic resilience could make a case for more Fed rate hikes, U.S. treasury rates rose across the long end, putting unseasoned growth stocks under pressure. This led the IPOX® 100 U.S. (ETF: FPX, -2.05%) lower, to +9.47% YTD. Markets abroad showed more resilience, with gains in the IPOX® China (CNI: +1.84%) and the IPOX® International (ETF: FPXI), which climbed +0.26% to +1.87% YTD. Amid the European Central Bank's 10th consecutive hike, taking European rates to their highest level since the launch of the Euro, the IPOX® 100 Europe (ETF: FPXE) slipped -0.11% to +7.00% YTD.


GINDEX® PERFORMANCE REVIEW: Our innovative large-cap focused and super liquid portfolios which focus on acquirers of IPOs (IPO M&As) showed a similar pattern last week, with the U.S.-focused GINDEX® U.S. (GNDX) dropping -0.16% to +10.76% YTD, while the abroad-focused GINDEX® International (GNDXI) gained +2.04% to +5.12% since its 3/17 live launch.





IPOX® PORTFOLIO STOCKS IN FOCUS: The IPOX® 100 U.S. (ETF: FPX) was led by Twinkie snack maker Hostess Brands (TWNK US: +18.68%), which surged anew as takeover plans were confirmed, with food manufacturer J.M. Smucker (SJM US) emerging as buyer at a $5.6 billion price tag. Eye drug pharma firm Apellis Pharmaceuticals (APLS US: +11.40%) continues to recover from their July dip, as clarifying updates on severe drug side effects reinstalled confidence, leading to a buy rating upgrade at Wells Fargo. London-listed telecommunications giant Airtel Africa (AAF LN: +15.20%) led the IPOX® 100 Europe (ETF: FPXE) amid ongoing IPO developments for their Uganda unit, which would become the country's largest domestic IPO at a planned $216m raise. Conversely, UK-headquartered Africa-focused Telecommunications tower firm IHS (IHS US: -18.99%) dropped after losing its top client with 2500 towers in Nigeria. Swedish wind energy developer OX2 (OX2 SS: +13.30%) regained strength after announcing a wind farm sale in Poland. In the IPOX® International (ETF: FPXI), Chinese KFC and Pizza Hut operator Yum China (YUMC US: +11.49%) soared on plans of accelerating store expansion, estimating double-digit earnings growth. British uranium firm Yellow Cake (YCA LN: +9.01%) climbed as prices of the radioactive metal have surged to a 12-year high. Index heavyweight, German car maker Porsche (P911 GR: -2.17%) lagged as the car industry in the U.S. faces strike action. Japanese tech investor SoftBank (9434 JP: +2.92%) climbed to a new post-IPO high, profiteering from the success of the mega-IPO of chipmaker Arm, of which the firm retains 90% ownership.




GLOBAL IPO DEAL FLOW REVIEW AND OUTLOOK: The IPO pipeline is heating up, as 6 notable IPOs started trading last week, adding +22.96% measured by the difference between the final offering price and Friday’s close. With three listings, the U.S. was the most active market last week, hosting the largest IPO this year, UK-based chip maker Arm Holdings (ARM US: +19.12%), which climbed following a successful debut, raising a massive $4.9 billion for a $55 billion valuation. Majority owner SoftBank retains 90% of the firm and potentially left $1 billion on the table after pricing the firm attractive enough to ensure a debut buzz. Read our latest IPOX® Watch IPO Pre-Analysis Feature for more information. Another new listing with SoftBank's backing included neurology pharma firm and Amgen collaborator Neumora Therapeutics (NMRA US: -4.41%, $250m offer), as well as cancer radiotherapy developer RayzeBio (RYZB US: +33.33%, $311m), which surged above $1 billion market capitalization after an upsized offer. Other new listings included coconut product maker Thai Coconut (COCOCO TB: +68.18%, $59m offer), Turkish office stationery firm Gipta (GIPTA TI: +20.86%, $31m offer) and Japanese IT consultancy Rise Consulting Group (9168 JP: +0.71%, $75m offer).


This week may further define U.S. IPO Market sentiment as two major listings are set to debut. Tuesday: Personal shopper grocery delivery firm Instacart (CART US) is finally set to launch Tuesday, after upsizing their IPO price range to raise $660m, following the success of Arm's listing. Instacart first announced IPO plans in 2020, after which its valuation estimate dropped from $30 billion to the current $10 billion. Wednesday: Digital marketing firm Klaviyo (KVYO US) plans a $518m raise but valuation plans could shift on Arm/Instacart success. Saudi oil & gas services firm ADES is expected to set the price for their listing the same day, planning a $1.2b raise to become Saudi Arabia's largest IPO in 2023. Furthermore, German shoemaker Birkenstock (BIRK US) filed for their October IPO on NYSE, seeking up to $8 billion valuation.



THE IPOX® SPAC (SPAC): The Index of 50 constituents trading at both the pre- and post-consummation stage fell -2.91% to +12.29% YTD. Index movers included Swiss biotech MoonLake Immunotherapeutics (MLTX US: +9.93%) as it soared on competitor’s failed clinical trial. Plastic recycling company PureCycle Technologies (PCT US: -28.06%) tanked as it may not meet production milestones due to an earlier plant power outage and operation halts. Other News: 1) 2 SPACs Announced Merger Agreement including Focus Impact Acq. (FIAC US: +0.66%) with Vancouver carbon credit firm DevvStream (DESG CN). 2) First Light Acquisition Group completed merger with oncology firm Calidi Biotherapeutics (CLDI US: -54.48%). 3) 2 SPACs announced liquidation. 4) No new SPAC launched in the U.S.

Lightspeed Financial Services Group LLC is not affiliated with these third-party market commentators/educators or service providers. Data, information, and material (“Content”) are provided for informational and educational purposes only. This content neither is, nor should be construed as an offer, solicitation, or recommendation to buy or sell any securities or contracts. Any investment decisions made by the user through the use of such content are solely based on the user's independent analysis taking into consideration your financial circumstances, investment objectives, and risk tolerance. Lightspeed Financial Services Group LLC does not endorse, offer or recommend any of the services or commentary provided by any of the market commentators/educators or service providers, and any information used to execute any trading strategies are solely based on the independent analysis of the user.


Futures trading involves the substantial risk of loss and is not suitable for all investors.

Each investor must consider whether this is a suitable investment since you may lose all of or more than your initial investment.

Past performance is not indicative of future results.




Lightspeed newsletter

Latest posts

Never miss a beat

Stay on top of the latest news and market insights

View all posts

Trade stock, options and futures

Lightspeed offers active and professional traders highly accurate market data, complex order management, fast executions, and multiple routing destinations.

Lightspeed Financial Services Group LLC is not affiliated with these third-party market commentators/educators or service providers. Data, information, and material (“Content”) are provided for informational and educational purposes only. This content neither is, nor should be construed as an offer, solicitation, or recommendation to buy or sell any securities or contracts. Any investment decisions made by the user through the use of such content are solely based on the user's independent analysis taking into consideration your financial circumstances, investment objectives, and risk tolerance. Lightspeed Financial Services Group LLC does not endorse, offer or recommend any of the services or commentary provided by any of the market commentators/educators or service providers, and any information used to execute any trading strategies are solely based on the independent analysis of the user.

© 2024 Lightspeed Financial Services Group, LLC. All rights reserved.

Equities, equities options, and commodity futures products and services are offered by Lightspeed Financial Services Group LLC (Member FINRA, NFA and SIPC). Lightspeed Financial Services Group LLC’s SIPC coverage is available only for securities, and for cash held in connection with the purchase or sale of securities, in equities and equities options accounts. You may check the background of Lightspeed Financial Services Group LLC on FINRA’s BrokerCheck.


Options trading entails significant risk and is not appropriate for all investors. Certain complex options strategies carry additional risk. Before trading options, please read Characteristics and Risks of Standardized Options


ETFs are subject to market fluctuation and the risks of their underlying investments. ETFs are subject to management fees and other expenses.

Defining the Shapes of Recessions & Recoveries

Written byMontana Timpson
Published on9 November 2022